ABSTRACT
Type 2 diabetes mellitus (T2DM) represents a significant global health burden, necessitating innovative therapeutic approaches. Recent research has increasingly recognized the role of gut microbiota modulation in T2DM management, offering promising avenues for intervention. This systematic review synthesizes current literature investigating the impact of modulating gut microbiota on T2DM management. A comprehensive search of databases yielded studies examining various strategies, including probiotics, prebiotics, dietary interventions, and facal microbiota transplantation. Analysis of these interventions revealed their potential to improve glycemic control, insulin sensitivity, and inflammation markers in individuals with T2DM. Mechanistic insights elucidate how gut microbiota modulation influences metabolic pathways, immune function, and gut barrier integrity, thereby contributing to T2DM pathophysiology. Furthermore, studies highlight the interplay between gut microbiota composition and host factors such as diet, lifestyle, and genetics, underscoring the complexity of this relationship. Modulating gut microbiota presents a promising therapeutic approach in T2DM management, with potential benefits in glycemic control and metabolic health. However, further research is warranted to optimize intervention strategies, elucidate mechanistic pathways, and explore long-term effects. The aim of this review was to underscores the importance of considering gut microbiota modulation as a complementary approach in the multifaceted management of T2DM.
ABSTRACT
Background: Diabetes mellitus (DM) is most common endocrine disorder all over the world. Metformin has been used as a first line drug, however, it has several gastrointestinal side effects. This study aims to determine the frequency of metformin induced gastrointestinal side effects among type 2 diabetic patients and role of prebiotics and probiotics in the prevention of the metformin-induced GI side effects. Methods: This cross-sectional study was performed in a tertiary care hospital, Rawalpindi, among 130 for one year from January 2021 to December 2022. Data was collected by applying a self-structured questionnaire. Descriptive statistics were used for the data analysis. Data analysis was performed via statistical package for the social sciences (SPSS) version 25.0. Results: The means for study variables like age, dose, and duration of therapy were 54.09 years, 1000 mg and 3.6 years respectively. Female patients had more GI side effects than male patients. Similarly, GI side effects frequency was also higher among the patients who were on metformin alone than the patients who were using metformin and combination of prebiotics and probiotics. Patients with higher dose of metformin and shorter duration of metformin therapy had higher frequency of GI symptoms. The most common GI symptom was constipation followed by diarrhea, bloating, abdominal pain, vomiting/nausea, dyspepsia, loss of appetite and flatulence. Conclusions: Metformin induced GI symptoms were common among study population. Use of prebiotics and probiotics combination with metformin, low dose of metformin, and longer duration of metformin use were found protective against the metformin-induced GI side effects.
ABSTRACT
El consumo de probióticos, prebióticos y posbióticos, o su combinación, puede contribuir a mantener una microbiota intestinal saludable ya que permite la regulación de su disbiosis en el caso de algunas enfermedades o trastornos, principalmente en los trastornos gastrointestinales funcionales (TGIF). El microbioma intestinal es protagonista esencial en la fisiopatología de los TGIF a través de sus funciones metabólicas y nutricionales, el mantenimiento de la integridad de la mucosa intestinal y la regulación de la respuesta inmunitaria. Las investigaciones realizadas hasta la fecha indican que los probióticos, prebióticos y posbióticos pueden tener efectos inmunomoduladores directos y clínicamente relevantes. Existen pruebas del uso de esta familia de bióticos en individuos sanos para mejorar la salud general y aliviar los síntomas en una serie de enfermedades como los cólicos infantiles. La colonización y establecimiento de la microbiota comienza en el momento del nacimiento; los primeros 2-3 años de vida son fundamentales para el desarrollo de una comunidad microbiana abundante y diversa. Diversos estudios científicos realizados mediante técnicas tradicionales dependientes de cultivo y más recientemente por técnicas moleculares han observado diferencias en las poblaciones bacterianas de bebés sanos y aquellos que sufren TGIF, estos últimos caracterizados por un aumento de especies patógenas y una menor población de bifidobacterias y lactobacilos, en comparación con los primeros. En tal contexto, se considera que la microbiota intestinal como protagonista en el desarrollo de esos trastornos, entre ellos los cólicos infantiles, a través de sus funciones metabólicas, nutricionales, de mantenimiento de la integridad de la mucosa intestinal y regulación de la respuesta inmunitaria. Esto ha abierto la puerta al estudio de la utilización de prebióticos, probióticos y posbióticos en el tratamiento y/o prevención de los TGIF infantiles. El parto vaginal y de término así como la lactancia son fundamentales en la constitución de una microbiota saludable. Como herramientas de apoyo, existen estudios de eficacia que sustentan la administración de esta familia de bióticos, principalmente en los casos en que la lactancia no sea posible o esté limitada. (AU)
The consumption of probiotics, prebiotics, and postbiotics, or a combination of them, can contribute to maintaining a healthy intestinal microbiota as it allows the regulation of its dysbiosis in the case of some diseases or disorders, mainly in functional gastrointestinal disorders (FGIDs). The gut microbiome is an essential player in the pathophysiology of FGIDs through its metabolic and nutritional functions, the maintenance of intestinal mucosal integrity, and the regulation of the immune response. Research results thus far indicate that probiotics, prebiotics, and postbiotics may have direct and clinically relevant immunomodulatory effects. There is evidence regarding the prescription of this family of biotics in healthy individuals to improve overall health and alleviate symptoms in many conditions like infantile colic. The colonization and microbiota establishment begins at birth; the first 2-3 years of life are critical for developing an abundant and diverse microbial community. Several scientific studies performed by traditional culture-dependent techniques and more recently by molecular techniques have observed differences in the bacterial populations of healthy infants and those suffering from FGIDs, the latter characterized by an increase in pathogenic species and a lower population of bifidobacteria and lactobacilli, compared to the former. In this context, the intestinal microbiota plays a leading role in the onset of these disorders, including infantile colic, through its metabolic and nutritional functions, maintenance of the integrity of the intestinal mucosa, and regulation of the immune response. That has opened the door to the study of prebiotics, probiotics, and postbiotics usage in the treatment and or prevention of infantile FGIDs. Vaginal and term delivery and breastfeeding are fundamental in the constitution of a healthy microbiota. As supportive tools, there are efficacy studies that support the administration of this family of biotics, mainly in cases where lactation is not possible or is limited.
Subject(s)
Humans , Colic/microbiology , Probiotics , Prebiotics , Synbiotics , Gastrointestinal Microbiome , Gastrointestinal Diseases/microbiology , Lactation , Colic/diet therapy , Colic/physiopathology , Colic/prevention & control , Functional Food , Gastrointestinal Diseases/diet therapy , Gastrointestinal Diseases/physiopathology , Gastrointestinal Diseases/prevention & controlABSTRACT
La enfermedad celíaca y la sensibilidad al gluten no celíaca han tenido un aumento en su incidencia, esto las ha convertido en tema de interés en la búsqueda de enfoques terapéuticos innovadores que ayuden a mejorar los síntomas intestinales y extraintestinales. Esta revisión pretende determinar los efectos del uso de probióticos y prebióticos en la enfermedad celíaca y sensibilidad al gluten no celíaca. Se realizó una búsqueda en bases de datos HINARI, PubMed y Scopus en idioma español e inglés, se incluyeron artículos originales y de revisión con un máximo de cinco años desde su publicación. El uso de probióticos y prebióticos para la enfermedad celíaca ha mostrado beneficios restaurando la composición del microbiota intestinal, en especial con el uso de Lactobacilli y Bifidobacterium spp.; en la sensibilidad al gluten no celíaca, el uso se ve limitado al no conocer con exactitud su fisiopatología; no obstante, se propone como mejor pauta terapéutica una dieta libre de gluten. El uso de probióticos y prebióticos podría aliviar los síntomas gastrointestinales y mejorar la disbiosis en pacientes con enfermedad celíaca y sensibilidad al gluten no celíaca. Sin embargo, se necesitan más estudios que evidencien los beneficios de su uso como alternativa terapéutica
Celiac disease and non-celiac gluten sensitivity are entities that have shown an increase in incidence, making them a topic of interest to provide innovative therapeutic approaches and improve intestinal and extraintestinal symptoms. This review intends to determine the effects of the use of probiotics and prebiotics in celiac disease and non-celiac gluten sensitivity. A narrative review was undertaken by searching for original and review articles no older than five years since publication through data bases consulted: HINARI, PubMed and Scopus in Spanish and English. The use of probiotics and prebiotics in celiac disease has shown benefits by restoring the composition of the intestinal microbiota, especially with the use of Lactobacilli and Bifidobacterium spp.; in non-celiac gluten sensitivity, its use is limited as its pathophysiology is not exactly known, therefore, a gluten-free diet is currently considered to be the best therapeutic guideline. The use of probiotics and prebiotics could alleviate gastrointestinal symptoms and improve dysbiosis in patients with celiac disease and non-celiac gluten sensitivity. However, more studies are needed to demonstrate the benefits of its use as a therapeutic alternative
Subject(s)
El SalvadorABSTRACT
El microbiota intestinal se encuentra constituida por más un millón de microorganismos entre los cuales las bacterias son de mayor prevalencia. Esta microbiota depende directamente de la localización exacta a lo largo del tubo digestivo, siendo la porción del colon la que alberga la mayor cantidad del microorganismo de la flora. El microbiota de la piel guarda relación directa con el microbiota del intestino por los diversos mecanismos existentes en la formación de la misma. El objetivo del presente estudio fue analizar el uso de probióticos y prebióticos en tratamiento de patología cutáneas y la relación entre la microbiota intestinal y enfermedades de la piel. Se realizó una revisión bibliográfica narrativa de la literatura científica de la relación del microbiota intestinal en patologías cutáneas. Se concluyó que el uso de probióticos y prebióticos juegan un papel importante en enfermedad cutáneas es especial de tipo inflamatoria.
The intestinal microbiota is constituted by more than one million microorganisms among which bacteria are the most prevalent. This microbiota is directly dependent on the exact location along the digestive tract, with the colon portion harboring the largest amount of the microorganism flora. The skin microbiota is directly related to the gut microbiota by the various mechanisms involved in its formation. The aim of the present study was to analyze the use of probiotics and prebiotics in the treatment of skin pathology and the relationship between the intestinal microbiota and skin diseases. A narrative bibliographic review of the scientific literature on the relationship between the intestinal microbiota and skin pathologies was carried out. It was concluded that the use of probiotics and prebiotics play an important role in skin diseases, especially inflammatory ones.
A microbiota intestinal é formada por mais de um milhão de microorganismos entre os quais as bactérias são as mais prevalentes. Esta microbiota depende diretamente da localização exata ao longo do trato gastrointestinal, sendo que a porção de cólon abriga a maior quantidade da flora de microorganismos. A microbiota da pele está diretamente relacionada à microbiota intestinal pelos diversos mecanismos envolvidos em sua formação. O objetivo deste estudo foi analisar o uso de probióticos e prebióticos no tratamento da patologia da pele e a relação entre a microbiota intestinal e as doenças de pele. Foi realizada uma revisão narrativa da literatura científica sobre a relação entre microbiota intestinal e patologias da pele. Concluiu-se que o uso de probióticos e prebióticos desempenha um papel importante nas doenças de pele, especialmente nas doenças inflamatórias da pele.
ABSTRACT
Aims@#Prebiotics and probiotics profoundly enhance water quality and shrimp development to tackle infectious disease in shrimp farming. This study evaluated the impact of prebiotics and probiotics treatments in water by assessing the physicochemical properties and bacterial communities in local shrimp ponds.@*Methodology and results @#Water was collected from shrimp pond 1 (SP1), treated with prebiotics and probiotics, and shrimp pond 2 (SP2), treated with only prebiotics. The physicochemical parameters of water from two shrimp ponds were measured, including pH, dissolved oxygen (DO), ammonia concentration and temperature. The total environmental DNA (eDNA) was extracted from the water samples and sequenced using amplicon sequencing targeting the full length of the 16S rRNA gene region via the Oxford Nanopore Technology Flongle. The water quality analysis indicated that SP1 had better water quality than SP2 for shrimp aquaculture. The dominant phyla in both shrimp ponds were Proteobacteria and Bacteroidota. SP1 samples had unique microbiota at the phylum level, including Bdellovibrionota, Firmicutes A, Patescibacteria and unclassified Rhizobiales, Saprospiraceae, Vulcanococcus and HIMB114 at the genus level. The alpha- and beta-diversity showed insignificant differences in microbiota composition between SP1 and SP2 (p-value>0.05).@*Conclusion, significance and impact of study @#Research findings demonstrated that the probiotic-treated shrimp pond (SP1) had better water quality and more diverse microbial communities than the shrimp pond that was not treated with probiotics (SP2).
ABSTRACT
Intra-abdominal infection is the second common infectious disease in intensive care unit and inhospital patients, with the mortality rate of 20%-30%. Advances in medicine have not improved the outcomes of patients with intra-abdominal infection, and the increasing multi-drug resistance organism may lead to a deterioration in the prognosis of patients with intra-abdominal infection. Gut microbiota dysbiosis and abdominal cavity infections show an interdependent and mutually aggravating relationship. Intestinal microecological preparations regulate gut flora and are potential therapeutic measures for intra-abdominal infections. The authors review the changes in gut flora during intra-abdominal infection, the effect of gut flora on the prognosis of intra-abdominal infections and the role of intestinal microecological preparations in intra-abdominal infections.
ABSTRACT
Objetivo: Oferecer uma visão geral sobre os efeitos que as intervenções com o uso de probióticos, prebióticos ou Transplante de Microbiota Fecal (TMF) e suas combinações provocam nos sintomas neurocomportamentais e gastrointestinais (GI) em indivíduos com Transtorno do Espectro Autista (TEA). Metodologia: Foi realizada uma revisão integrativa (RI) da literatura nas plataformas PubMed, SciELO, LILACS e Scopus, a partir dos descritores "autistic disorder", "autism", "prebiotics", "probiotics", "fecal microbiota transplantation" e "fecal transplantation", utilizando os operadores booleanos "AND" e "OR". Foram selecionados apenas artigos dos anos de 2013 a 2022, publicados em português, inglês ou espanhol e que possuíam relação direta com o tema. Resultados: Foram analisados 24 artigos na íntegra, dos quais 14 obedeciam aos critérios de inclusão e tiveram seus resultados analisados na presente revisão. Desses, dois relataram melhora dos sintomas GI com uso de probiótico, prebiótico e/ou TMF, nove mencionaram melhora tanto dos sintomas GI como dos neurocomportamentais com as terapias utilizadas e os outros três avaliaram a mudança dos sintomas neurocomportamentais. Conclusão: As terapias com probióticos, prebióticos e TMF possuem um efeito promissor na modificação da microbiota e na melhora dos sintomas neurocomportamentais e GI em pessoas com TEA.
Objective: To provide an overview of the effects that interventions with the use of probiotics, prebiotics, or fecal microbiota transplantation and their combinations have on neurobehavioral and gastrointestinal (GI) symptoms in individuals with Autism Spectrum Disorder (ASD). Methodology: An integrative review of the literature was conducted on the PubMed, SciELO, LILACS, and Scopus platforms using the descriptors "autistic disorder", "autism", "prebiotics", "probiotics", "fecal microbiota transplantation", and "fecal transplantation", using the Boolean operators "AND" and "OR". Only articles published between 2013 and 2022 in Portuguese, English, or Spanish and directly related to the topic were selected. Results: Twenty-four articles were fully analyzed, of which fourteen met the inclusion criteria and had their results analyzed in this review. Of these, two reported improvement in GI symptoms with the use of probiotics, prebiotics, and/or fecal microbiota transplantation, nine mentioned improvement in both GI and neurobehavioral symptoms with the therapies used, and the other three evaluated the change in neurobehavioral symptoms. Conclusion: Probiotic, prebiotic, and fecal microbiota transplantation therapies have a promising effect on modifying the microbiota and improving neurobehavioral and GI symptoms in individuals with ASD.
Objetivo: Proporcionar una visión general de los efectos que las intervenciones con el uso de probióticos, prebióticos o trasplante de microbiota fecal y sus combinaciones tienen sobre los síntomas neuroconductuales y gastrointestinales (GI) en individuos con Trastorno del Espectro Autista (TEA). Metodología: Se realizó una revisión integradora de la literatura en las plataformas PubMed, SciELO, LILACS y Scopus utilizando los descriptores "autistic disorder", "autism", "prebiotics", "probiotics", "fecal microbiota transplantation" y "fecal transplantation", utilizando los operadores booleanos "AND" y "OR". Solo se seleccionaron artículos publicados entre 2013 y 2022 en portugués, inglés o español y directamente relacionados con el tema. Resultados: Veinticuatro artículos fueron analizados en su totalidad, de los cuales catorce cumplieron los criterios de inclusión y sus resultados fueron analizados en esta revisión. De estos, dos reportaron mejoría en los síntomas GI con el uso de probióticos, prebióticos y/o trasplante de microbiota fecal, nueve mencionaron mejoría tanto en los síntomas GI como neuroconductuales con las terapias utilizadas, y los otros tres evaluaron el cambio en los síntomas neuroconductuales. Conclusiones: Las terapias con probióticos, prebióticos y trasplante de microbiota fecal tienen un efecto prometedor en la modificación de la microbiota y la mejora de los síntomas neuroconductuales y GI en individuos con TEA. PALABRAS CLAVE: Autismo; Microbiota; Prebióticos; Probióticos; Trasplante de Microbiota Fecal.
ABSTRACT
La hipertensión arterial esencial es una patología de alta prevalencia a nivel mundial, y uno de los determinantes más significativos para enfermedad cardiovascular. Por otra parte, se ha generado un gran interés por la microbiota del cuerpo, y la forma en que se ve alterada por factores tanto internos como externos, ocasionando disbiosis. En la actualidad se viene estudiando el efecto de la microbiota en diferentes enfermedades, entre ellas, la relación entre la microbiota y la hipertensión. En este artículo se hizo una revisión de la literatura, entre 2010 a 2021, con el objetivo de identificar la evidencia científica que sustenta la relación entre la composición de la microbiota y la hipertensión arterial esencial. Se encontró en muchos estudios que los hipertensos tenían una diversidad menor de la microbiota, en comparación con los grupos de control sanos. En los hipertensos se encontraron principalmente bacterias del género Prevotella y en el grupo control predominaba el género Bacteroidetes. Adicionalmente, se observó una disminución de Faecalibacterium, Roseburia y Bifidobacterium en el grupo de hipertensos. Existen varias técnicas de laboratorio para el reconocimiento de la población bacteriana del intestino, tales como la secuenciación de la subunidad de ARNr 16S, la secuenciación del genoma completo y la metagenómica de la microbiota. A pesar de que los estudios realizados sobre la relación microbiota e hipertensión concluyen que existe una relación significativa entre ambas, es necesario hacer más investigaciones en diferentes grupos poblacionales
Essential arterial hypertension is a highly prevalent pathology worldwide and is one of the most significant determinants of cardiovascular disease. On the other hand, great interest has been generated in the microbiota of the body, and how it is altered by both internal and external factors, causing dysbiosis. Currently, the effect of the microbiota in different diseases is being studied, including the relationship between the microbiota and hypertension. In this article, a review of the literature was made, between 2010 and 2021, with the objective of identifying the scientific evidence that supports the relationship between the composition of the microbiota and essential arterial hypertension. It was found in many studies that individuals with high blood pressure had lower microbiota diversity compared to healthy control groups. In hypertensive patients, bacteria of the genus Prevotella were mainly found, while in the control group the genus Bacteroidetes predominated. Additionally, a decrease in Faecalibacterium, Roseburia and Bifidobacterium was observed in the hypertensive group. There are several laboratory techniques for the analysis of the intestinal bacterial population, such as 16S rRNA subunit sequencing, whole genome sequencing, and microbiota metagenomics. Despite the fact that the studies conclude that there is a significant relationship between microbiota and hypertension, it is necessary to do more research in different population groups
Subject(s)
Humans , Essential Hypertension , Humans , Epidemiology , Risk Factors , Probiotics , Prebiotics , Microbiota , InflammationABSTRACT
La interrupción de la simbiosis que existe entre el cuerpo humano y su microbioma puede resultar en una disbiosis, un desequilibrio en la interacción huésped-microbiota, que puede asociarse al desarrollo de diversas enfermedades como el síndrome de intestino irritable, hígado graso no alco-hólico, enfermedad hepática alcohólica y cirrosis, entre otras. En ciertas condiciones patológicas y por múltiples factores de riesgo, la capacidad de autorregulación del intestino se puede alterar, contribuyendo al incremento de la permeabilidad con inflamación intestinal crónica. El diagnóstico y el tratamiento, así como la relación entre la permeabilidad intestinal, la disbiosis y las patologías gastrointestinales y hepatobiliares, todavía no tienen estudios clínicos validados o con el soporte científico adecuado, por lo que se realiza una revisión de la literatura con la finalidad de aportar conceptos que puedan orientar con respecto a la importancia del estudio del microbioma humano en estas enfermedades.
Disruption of the symbiosis that exists between the human body and its microbiome can result in dys-biosis, an imbalance in the host-microbiota interaction, which may be associated with the develop-ment of various diseases such as irritable bowel syndrome, non-alcoholic fatty liver disease, alcoholic liver disease and cirrhosis, among others. In certain pathological conditions and due to multiple risk factors, the self-regulating capacity of the intestine may be lost, contributing to increased permeability with chronic intestinal inflammation. Its diagnosis and treatment as well as the relationship between intestinal permeability, dysbiosis and gastrointestinal and hepatobiliary pathologies have not been validated in clinical studies or have adequate scientific support, so a review of the literature is carried out in order to provide concepts that can guide with respect to the importance of the study of the human microbiome in these diseases
Subject(s)
Humans , Permeability , Dysbiosis , Microbiota , Gastrointestinal Microbiome , Risk Factors , Irritable Bowel Syndrome , Fatty Liver , Non-alcoholic Fatty Liver Disease , Gastrointestinal Diseases , Liver Diseases, AlcoholicABSTRACT
Recientes investigaciones han relacionado la microbiota intestinal con la salud humana en múltiples aspectos. La evolución de los estilos de vida ha determinado un cambio en la composición de las bacterias intestinales, así como la implicación que la comunidad de estas ejerce sobre la salud. Actualmente, se conoce que la mayoría de las bacterias presentes en el sistema gastrointestinal pertenecen principalmente a los fila Firmicutes y Bacterioidetes, aunque también se encuentran otros grupos tales como proteobacterias y actinobacterias. A medida que se avanza en el tracto gastrointestinal predominan algunos géneros de bacterias. Los efectos de la microbiota pueden ser directos e indirectos, además, dependen de muchos factores tales como la edad de la persona, el grupo etario, la genética del individuo, la dieta y el estilo de vida. Durante los últimos años, la accesibilidad a tecnologías de secuenciación ha permitido tener un acercamiento más estrecho a la microbiota intestinal. Esto, sumado a herramientas bioinformáticas, ha permitido establecer relaciones microbiales entre la cantidad y estructura poblacional y las manifestaciones clínicas en el ser humano. Algunas de las afecciones estudiadas y que tienen relación con la microbiota intestinal son: la obesidad, la diabetes, el cáncer, las enfermedades relacionadas con el cerebro, las enfermedades cardiovasculares y las enfermedades gastrointestinales. De acuerdo con lo mencionado, se hizo una recopilación de información de carácter científico en cuanto a estudios relevantes que describen la relación microbiota-salud humana y casos donde se observa compromiso del organismo, al mismo tiempo que se describen opciones terapéuticas propuestas y un abordaje de perspectivas futuras.
Recent research has linked gut microbiota to human health in multiple ways. The evolution of lifestyles has determined a change in the composition of intestinal bacteria, as well as the implications that they exert on health. Currently, it is known that most of the bacteria present in the gastrointestinal sector belong mainly to the phylum Firmicutes and Bacterioidetes, although there are also other groups such as proteobacteria and actinobacteria. As it progresses through the gastrointestinal tract, some genera of bacteria and species predominate. The effects of the microbiota can be direct and indirect, and also depend on many factors such as the age of the person, the age group, the individual's genetics, diet, and lifestyle. In recent years, accessibility to sequencing technologies has allowed for a closer approach to the intestinal microbiota. This, added to bioinformatic tools has allowed establishing microbial relationships in terms of quantity and population structure with clinical manifestations in humans. Some of the pathologies studied that are related to intestinal microbiota are obesity, diabetes, cancer, brain-related diseases, cardiovascular diseases, and gastrointestinal diseases. A compilation of scientific information is made regarding relevant studies that describe the microbiota-human health relationship, cases where the organism is affected, as well as proposed therapeutic options and an approach to future perspectives
Subject(s)
Gastrointestinal Microbiome , Probiotics , Prebiotics , MultiomicsABSTRACT
A obesidade tem causa multifatorial que atinge atualmente mais da metade da população brasileira. Mais recentemente, a microbiota intestinal foi considerada um fator que contribui para essa condição. Os objetivos deste estudo foram revisar a influência da microbiota intestinal na obesidade e no processo inflamatório, e analisar os efeitos da utilização dos pré e probióticos. Foi realizada revisão sistemática sobre o assunto. Dos mais de 27.000 artigos, apenas 16 respeitaram os critérios de inclusão. Em conclusão, o desequilíbrio da microbiota aparece como fator favorável ao desenvolvimento da obesidade e do quadro inflamatório decorrente dela. Tanto o uso de prebióticos quanto probióticos são recursos válidos no tratamento da obesidade, porém os primeiros parecem proporcionar melhor qualidade de vida.
Obesity has a multifactorial etiological condition that involves more than half of the Brazilian population. More recently, the intestinal microbiota was considered a factor that contributes to this condition. The aims of this study were to review the intestinal microbiota influence in the obesity and in the inflammatory response, and to analyze the effects of using prebiotic and probiotic medications. A systematic review was firstly done. More than 27,000 articles were found, but only 16 contained the proper criteria. In conclusion, the microbiota imbalance seems to increase the obesity development and its inflammatory aspects. Both the use of pre and probiotics are good options in the obesity treatment, though the first ones seem to enhance bettere quality of life.
Subject(s)
Gastrointestinal Transit , Probiotics , Prebiotics , Microbiota , Gastrointestinal Microbiome , Obesity , InflammationABSTRACT
RESUMEN Introducción: Los productos naturales con actividad farmacológica requieren de evaluaciones preclínicas que justifiquen su empleo sobre una base científica. El ensayo de pirógenos es una prueba dentro de la Farmacología de Seguridad que se realiza para determinar la presencia de endotoxinas y constituye un método valioso, para demostrar la seguridad de bioderivados con potencial prebiótico en el campo de la inmunonutrición. Objetivo: Evaluar la pirogenicidad de bioproductos fúngicos de Pleurotus ostreatus (extractos acuosos del micelio y cuerpos fructíferos) y un biopreparado de levadura Kluyveromyces marxianus, empleando el ensayo de pirógenos en conejos Nueva Zelanda. Método: Se ensayaron concentraciones de 1,0 y 10,0 mg/mL de cada muestra por vía endovenosa en dosis de 0,5 y 5,0 mg/kg de peso. El diseño experimental cumplió las buenas prácticas de laboratorio según lo establecido por el International Council for Laboratory Animals Science y se realizó de acuerdo a los procedimientos normalizados de trabajo del Centro de Toxicología y Biomedicina, Santiago de Cuba. Resultados: Los extractos de Pleurotus ostreatus y el biopreparado de levadura (0,5 mg/kg) no mostraron signos de pirogenicidad. En los resultados del biopreparado (5,0 mg/kg), los valores de temperatura caen en un rango de incertidumbre, según la Farmacopea de Estados Unidos (USP) y se sugirió repetir el estudio. Conclusiones: Los extractos de Pleurotus ostreatus y el biopreparado de Kluyveromyces marxianus (0,5 mg/kg) no indujeron un aumento de temperatura significativo en los animales, lo cual sugiere que en estos bioproductos no existen niveles de endotoxinas que puedan provocar pirogenicidad.
ABSTRACT Introduction: Natural products with pharmacological activity require preclinical evaluations to justify their uses scientifically. The pyrogen assay is a safety pharmacology test performed to determine the presence of endotoxins and it is a valuable method to demonstrate the bio-derivative products safety and their prebiotic potential in the field of immunonutrition. Objective: To evaluate the pyrogenicity of fungal bioproducts from Pleurotus ostreatus (aqueous extracts from mycelium and fruiting bodies) and a biopreparation from Kluyveromyces marxianus yeast, using a pyrogen assay in New Zealand rabbits. Method: Concentrations of 1.0 and 10.0 mg/mL of each sample were tested intravenously at doses of 0.5 and 5.0 mg/kg body weight. The experimental design complied with good laboratory practices as established by the International Council for Laboratory Animal Science and was carried out according to the standard work procedures of the Centro de Toxicología y Biomedicina, Santiago de Cuba. Results: Pleurotus ostreatus extracts and the yeast biopreparation (0.5 mg/kg) showed no signs of pyrogenicity. In the biopreparation results (5.0 mg/kg), temperature values fall in the uncertainty range according to the United States Pharmacopoeia (USP), and therefore it was suggested to repeat the study. Conclusions: Pleurotus ostreatus extracts and Kluyveromyces marxianus biopreparation (0.5 mg/kg) did not induce a significant temperature increase in the animals, thereby suggesting that there are no endotoxin levels in such bioproducts that could cause pyrogenicity.
RESUMO Introdução: Produtos naturais com atividade farmacológica requerem avaliações pré-clínicas que justifiquem seu uso em bases científicas. O ensaio de pirogênio é um teste dentro da Farmacologia de Segurança que é realizado para determinar a presença de endotoxinas e é um método valioso para demonstrar a segurança de bioderivados com potencial prebiótico no campo da imunonutrição. Objetivo: Avaliar a pirogenicidade de bioprodutos fúngicos de Pleurotus ostreatus (extratos aquosos do micélio e corpos de frutificação) e de uma biopreparação da levedura Kluyveromyces marxianus, utilizando o ensaio pirogênico de coelho da Nova Zelândia. Método: Concentrações de 1,0 e 10,0 mg/mL de cada amostra foram testadas por via intravenosa nas doses de 0,5 e 5,0 mg/kg de peso. O desenho experimental obedeceu às boas práticas laboratoriais estabelecidas pelo Conselho Internacional para a Ciência dos Animais de Laboratório e foi realizado de acordo com os procedimentos de trabalho padrão do Centro de Toxicologia e Biomedicina, Santiago de Cuba. Resultados: Os extratos de Pleurotus ostreatus e a biopreparação de leveduras (0,5 mg/kg) não apresentaram sinais de pirogenicidade. Nos resultados da biopreparação (5,0 mg/kg), os valores de temperatura estão dentro de uma faixa de incerteza, segundo a Farmacopeia dos Estados Unidos (USP) e foi sugerido repetir o estudo. Conclusões: Os extratos de Pleurotus ostreatus e a biopreparação de Kluyveromyces marxianus (0,5 mg/kg) não induziram um aumento significativo da temperatura nos animais, o que sugere que não há níveis de endotoxinas nesses bioprodutos que possam causar pirogenicidade.
ABSTRACT
ABSTRACT Background Supplementation with probiotics, prebiotics and symbiotics has shown positive effects on clinical markers and risk factors for non-alcoholic fatty liver disease (NAFLD). Objective To evaluate the effect of supplementation with probiotic, prebiotic or symbiotic on intestinal microbiota in NAFLD patients. Methods Two investigators conducted independently search for articles in the Medline databases, via PubMed, Web of Science, Embase, Scopus, Lilacs, Central Cochrane Library, Clinical Trials.gov and on the Ovid platform for the gray literature search. Results A total of 3,423 papers were identified by searching the electronic databases; 1,560 of them were duplicate and they were excluded; 1,825 articles were excluded after reading the title and abstract. A total of 39 articles were select to reading, however only four articles met the eligibility criteria to include in this systematic review. Three of the included studies that used prebiotic or symbiotic supplementation showed that after the intervention there were changes in the intestinal microbiota pattern. Only in one study such changes were not observed. A high risk of bias was observed in most assessments. Conclusion Although there is a possible change in the gut microbiota of individuals with NAFLD after supplementation with symbiotics or prebiotics, a clinical indication as part of NAFLD treatment is not yet possible.
RESUMO Contexto A suplementação com probióticos, prebióticos e simbióticos mostrou efeitos positivos sobre marcadores clínicos e fatores de risco para doença hepática gordurosa não alcoólica (DHGNA). Objetivo Avaliar o efeito da suplementação com probióticos, prebióticos ou simbióticos na microbiota intestinal em pacientes com DHGNA. Métodos Dois pesquisadores realizaram buscas independentes de artigos nas bases de dados Medline, via PubMed, Web of Science, Embase, Scopus, Lilacs, Biblioteca Central Cochrane, Clinical Trials.gov e na plataforma Ovid para busca de literatura cinza. Os títulos e resumos foram lidos para excluir artigos irrelevantes. Em seguida, os artigos selecionados foram lidos na íntegra e avaliados de acordo com os critérios de elegibilidade. O risco de viés foi avaliado de acordo com a Cochrane. Resultados Um total de 3.423 artigos foram identificado por meio de busca nas bases de dados eletrônicas; 1.560 deles eram duplicados e foram excluídos; 1.825 artigos foram excluídos após a leitura do título e do resumo. Um total de 39 artigos foram selecionado para leitura, porém apenas quatro artigos atenderam aos critérios de elegibilidade para inclusão nesta revisão sistemática. Três dos estudos incluídos que utilizaram suplementação de prebióticos ou simbióticos mostraram que após a intervenção ocorreram mudanças no padrão da microbiota intestinal. Apenas em um estudo tais mudanças não foram observadas. Um elevado risco de viés foi observado na maioria das avaliações. Conclusão Embora haja uma possível alteração na microbiota intestinal de indivíduos com DHGNA após a suplementação com simbióticos ou prebióticos, uma indicação clínica como parte do tratamento da DHGNA ainda não é possível.
ABSTRACT
Inflammatory bowel disease (IBD) is a non⁃specific chronic inflammatory disease of the intestine, and its pathogenesis is not yet been fully elucidated. At present, it is generally believed that gut microbiota plays a key role in the pathogenesis of IBD. Prebiotics are non⁃digestible food ingredients that can regulate the gut microbiota. Recently, more and more studies support the beneficial effect of prebiotics in IBD. Some prebiotics of dietary supplements can be used as fermentable substrates to promote the growth and metabolic activity of intestinal beneficial bacteria and increase the production of short ⁃ chain fatty acids, thereby exerting anti ⁃ inflammatory effects. This article reviewed the progress in research on the protective mechanism of prebiotics in IBD from the perspective of traditional and emerging prebiotics and providing a theoretical basis for its application in IBD adjuvant therapy.
ABSTRACT
With the in-depth study on the gut microflora, the impact of intestinal bacteria on human health has attracted more and more attention. It has become a research hotspot in life science and medicine, and is considered as an important target of disease control. Prebiotics can regulate the composition and function of intestinal flora and then improve host health. Carbohydrate is the most basic prebiotic. Its unique physiochemical characteristics and gut microbiota-regulating ability make it a promising ingredient for achieving drug target delivery and intestinal health promotion. In this paper, different kinds of prebiotics and their regulation mechanism of intestinal bacteria were illuminated. Moreover, the research progress of carbohydrate prebiotics in drug delivery system was elucidated, and its application prospect is prospected, so as to provide reference for related research.
ABSTRACT
Gut microbiota is a bridge between the metabolism and health state of the host,which plays a very important role in maintaining homeostasis. Natural polysaccharides,widely existed in nature,are a kind of biological macromolecules with prebiotics effects,which can improve a degree of physiological status by selectively changing the gut microbiota structure and function,enhancing the content of short chain fatty acids(SCFAs)and decreasing the level of inflammatory cytokines. In addition,the majority of polysaccharides can be degraded by gut microbiota to enhance their bioavailability and to promote the health state of the host. In this paper we discuss the interaction among polysaccharides and gut microbiotanatural,degradation mechanism and review gut microbiota as a target in the treatment of metabolic diseases,so as to provide future prospects of natural polysaccharides as " prebiotics " functional factors in the field of biological medicine and health products.
ABSTRACT
ABSTRACT Objective: To assess the effect of toothpaste containing 8% arginine on Streptococcus mutans (S. mutans) in dental plaque around orthodontic brackets, and to draw a comparison with a regular fluoride toothpaste. Trial design: A single-center, parallel-arm, triple-blind, randomized controlled trial was conducted. Methods: The clinical trial was conducted at the Orthodontic Clinic, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran. Seventy-two patients (age range: 15-30 years) who required fixed orthodontic treatment were recruited and randomly assigned to arginine and fluoride groups. Randomization was performed using RANDOM.ORG online software, and the participants were divided into two parallel groups, with a 1:1 allocation ratio. Patients were requested to brush their teeth twice daily for 30 days with an experimental toothpaste. Plaque sampling was performed at two intervals, namely at the beginning of the study (T0) and 30 days later (T1). Real-time PCR was used to assess plaque samples in terms of the number of S. mutans surrounding stainless steel brackets in orthodontic patients. A triple-blind design was employed. Results: The baseline characteristics (age, sex, and the relative number of S. mutans) between the groups were similar (p>0.05). Only the arginine group showed a significant decrease in the relative number of bacteria between T0 and T1 (p=0.02). Conclusion: Arginine is an important prebiotic agent in maintaining healthy oral biofilms, and prevent dental caries during fixed orthodontic treatments. Trial registration: The trial was registered at the Iranian Registry of Clinical Trials (IRCT20181121041713N2), https://en.irct.ir/user/trial/42409/view.
RESUMO Objetivo: Avaliar o efeito de um dentifrício contendo arginina a 8% no Streptococcus mutans (S. mutans) da placa bacteriana ao redor de braquetes ortodônticos, e compará-lo a um dentifrício fluoretado convencional. Desenho do estudo: Foi conduzido um estudo unicêntrico, com braços paralelos, triplo-cego, controlado e randomizado. Métodos: O ensaio clínico foi conduzido na Clínica de Ortodontia da Faculdade de Odontologia da Universidade de Ciências Médicas de Shiraz, no Irã. Setenta e dois pacientes (com idades variando de 15 a 30 anos) que necessitavam de tratamento ortodôntico com aparelho fixo foram recrutados e alocados aleatoriamente nos grupos arginina ou flúor. A randomização foi feita usando o programa on-line RANDOM.ORG, e os participantes foram divididos em dois grupos paralelos, com proporção de alocação de 1:1. Solicitou-se aos pacientes que escovassem os dentes duas vezes ao dia com a pasta experimental, durante 30 dias. Amostras da placa bacteriana foram coletadas em dois intervalos: ao começo do estudo (T0) e após 30 dias (T1). Um PCR em tempo real foi usado para avaliar as amostras de placa, em termos de números de S. mutans ao redor dos braquetes de aço inoxidável nos pacientes ortodônticos. Um desenho de estudo triplo-cego foi usado. Resultados: As características iniciais (idade, sexo e quantidade relativa de S. mutans) foram semelhantes entre os grupos (p>0,05). Apenas o grupo arginina mostrou uma redução significativa na quantidade de bactérias entre T0 e T1 (p=0,02). Conclusão: A arginina é um agente prebiótico importante na manutenção de biofilmes bucais saudáveis, e previne as cáries dentárias durante o tratamento ortodôntico com aparelho fixo. Registro do ensaio: O ensaio foi registrado no Iranian Registry of Clinical Trials (IRCT20181121041713N2), https://en.irct.ir/user/trial/42409/view.
ABSTRACT
Se evaluó el efecto de un gel con arginina sobre el pH y flujo salival después de un uso de catorce días en mujeres con desmineralización dental leve. Se estableció un piloto de ensayo clínico controladoen el cual fueron incluidas 20 mujeres de 18 -23 años, sistémicamente sanas y con al menos un órgano dental con desmineralización ICDAS 3, dos grupos: Grupo A / sin arginina (N=10) y Grupo B/ con arginina (N=10). Se realizó una evaluación clínica y toma de una muestra de saliva no estimulada para la determinación del pH, y la medición del flujo salival al inicio y 15 días posterior a la utilización del gel. Se realizó el análisis estadístico con el programa GraphPadPrism versión 8. Una p<0,05 fue considerado como estadísticamente significativo. En ambos grupos se mantuvo el pH salival cercano a la neutralidad sin diferencias estadísticamente significativas y el flujo salival permaneció en valores normales tras la utilización del gel durante 14 días, aunque se observaron diferencias estadísticas significativas en la comparación inter-grupo. La utilización de un gel con arginina durante 14 días mantuvo el pH neutro y el flujo salival en niveles normales sin diferencias estadísticamente significativas con el grupo control.
The effect of an arginine gel on pH and salivary flow was evaluated after fourteen days of use in women with mild demineralization. A controlled pilot clinical trial was established in which 20 women aged 18-23 years, systemically healthy and with at least one dental organ with demineralization ICDAS 3 were included, two groups: Group A / without arginine (N = 10) and Group B / with arginine (N = 10). A clinical evaluation was carried out, and a sample of unstimulated saliva was taken to determine the pH and the measurement of salivary flow at the beginning and 15 days after using the gel. Statistical analysis was performed with the GraphPad Prism version 8 program. A p <0.05 was considered statistically significant. In both groups, salivary pH was maintained close to neutrality without statistically significant differences, and salivary flow remained at normal values after using the hydrogel for 14 days, although statistically significant differences were observed in the intergroup comparison. Using a gel with arginine for 14 days kept the neutral pH and salivary flow at normal levels without statistically significant differences from the control group.
Subject(s)
Humans , Female , Adolescent , Young Adult , Arginine/therapeutic use , Saliva/enzymology , Saliva/metabolism , Specimen Handling , Symptomatology , Demography , Drug CompoundingABSTRACT
The utilization of antimicrobials in animal production, causes selection of resistant bacteria. The objective of this study was to compare the utilization of alternatives in association with preventive antibiotic therapy in swine feed during the growing and finishing phases. 1,045 animals were used from 60 to 190 days of age and were subjected to six treatments with 16 repetitions as follows: 1) antibiotic free; 2) antibiotics; 3) prebiotic; 4) probiotic; 5) essential oils; and 6) organic acid. Animals were weighted, and clinical history was recorded including mortality and diarrhea. At the abattoir, pneumonia index and gastric ulcers were investigated. The cost for each treatment was discussed. No difference between treatments were observed (P>0.05) regarding feed conversion rate (2.64±0.03), overall average weight gain (107.06±0.9kg), average daily weight gain (856.49±7.7g) and carcass weight (92.4±0.7kg). The application injectable drugs in animals presenting clinical symptoms, represented US$ 0.56/intervention, without difference between the treatments (P>0.05). Furthermore, independently of the treatment, high frequency of pneumonia was observed (>0.90). No difference for the degree of gastric ulcer nor feces consistency were observed (P>0.05). The utilization of antibiotic therapy and alternatives to antibiotics in feed did not produce benefits to the production indices and sanitary performances of the animals.(AU)
A utilização de antimicrobianos na produção animal provoca seleção de bactérias resistentes. O objetivo do estudo foi comparar a utilização de alternativas associadas à antibioticoterapia preventiva na alimentação de suínos nas fases de recria e de terminação. Foram utilizados 1.045 animais de 60 a 190 dias de idade, submetidos a seis tratamentos com 16 repetições, como segue: 1) sem antibióticos; 2) com antibióticos; 3) prebióticos; 4) probióticos; 5) óleos essenciais; e 6) ácidos orgânicos. Os animais foram pesados, e a história clínica foi registrada, incluindo mortalidade e diarreia. No abatedouro, foram investigados índices de pneumonia e úlceras gástricas. O custo de cada tratamento foi discutido. Não houve diferença entre os tratamentos (P>0,05) em relação à taxa de conversão alimentar (2,64 ± 0,03), ao ganho de peso médio geral (107,06 ± 0,9kg), ao ganho de peso médio diário (856,49 ± 7,7g) e ao peso de carcaça (92,4 ± 0,7kg). A aplicação de medicamentos injetáveis em animais com quadro clínico representou US$ 0,56/intervenção, sem diferença entre os tratamentos (P>0,05). Além disso, independentemente do tratamento, foi observada alta frequência de pneumonia (>0,90). Não foi observada diferença para o grau de úlcera gástrica nem na consistência das fezes (P>0,05). A utilização de antibioticoterapia e de alternativas aos antibióticos na ração não trouxe benefícios aos desempenhos zootécnico e sanitário dos animais.(AU)